Jerrold Grossman Buys 12,500 Shares of ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Jerrold Grossman acquired 12,500 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director directly owned 501,384 shares in the company, valued at approximately $4,016,085.84. This trade represents a 2.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ADMA Biologics Stock Performance

ADMA opened at $8.50 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The firm has a fifty day moving average price of $11.52 and a 200 day moving average price of $15.28. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $22.37. The stock has a market cap of $2.02 billion, a P/E ratio of 12.50 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. During the same quarter last year, the business earned $0.11 earnings per share. The firm’s revenue was down .3% on a year-over-year basis. Equities research analysts anticipate that ADMA Biologics Inc will post 0.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ADMA shares. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research downgraded ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Mizuho cut their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Canaccord Genuity Group reduced their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $19.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ADMA. Boothbay Fund Management LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $11,334,000. Thrivent Financial for Lutherans increased its position in shares of ADMA Biologics by 24.9% during the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock worth $60,719,000 after purchasing an additional 826,415 shares in the last quarter. Tealwood Asset Management Inc. acquired a new position in ADMA Biologics in the 4th quarter valued at $1,315,000. American Century Companies Inc. raised its stake in ADMA Biologics by 1.8% in the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after purchasing an additional 84,934 shares during the last quarter. Finally, Renaissance Group LLC lifted its holdings in ADMA Biologics by 50.4% in the 3rd quarter. Renaissance Group LLC now owns 516,588 shares of the biotechnology company’s stock valued at $7,573,000 after purchasing an additional 173,016 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.